Key facts
- It has raised $170K; the latest was Later Stage VC in Jan 2025.
- Notable investors include Iyengar Capital, Minnesota Department of Employment and Economic Development.
- Respiratory Sciences has filed 1 Form D with the SEC, most recently Feb 2021 ($165K sold to 5 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Respiratory Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Respiratory Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Respiratory Sciences
Developer of respiratory diagnostic and treatment technologies designed to improve patient outcomes. The company's tool integrates clinical insights and user-friendly interfaces, enabling healthcare providers to monitor and treat respiratory conditions more effectively, ultimately improving access to care in both medical facilities and home settings for facilitating timely interventions for patients.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2020
- Employees
- 7
- Website
- respiratorysciencesinc.com/
- Ownership
- Privately Held (backing)
Respiratory Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Respiratory Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Respiratory Sciences in its N-PORT filings yet. We sweep new filings monthly.